Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.

To determine the frequency and clinical-radiological associations of antibodies to myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) in children presenting with neuromyelitis optica (NMO) and limited forms. Children with a first event of NMO, recurrent (RON), bilateral ON (BON), longitudinally extensive transverse myelitis (LETM) or brainstem syndrome (BS) with a clinical follow-up of more than 12 months were enrolled. Serum samples were tested for MOG- and AQP4-antibodies using live cell-based assays. 45 children with NMO (n=12), LETM (n=14), BON (n=6), RON (n=12) and BS (n=1) were included. 25/45 (56%) children had MOG-antibodies at initial presentation (7 NMO, 4 BON, 8 ON, 6 LETM). 5/45 (11%) children showed AQP4-antibodies (3 NMO, 1 LETM, 1 BS) and 15/45 (33%) were seronegative for both antibodies (2 NMO, 2 BON, 4 RON, 7 LETM). No differences were found in the age at presentation, sex ratio, frequency of oligoclonal bands or median EDSS at last follow-up between the three groups. Children with MOG-antibodies more frequently (1) had a monophasic course (p=0.018) after one year, (2) presented with simultaneous ON and LETM (p=0.004) and (3) were less likely to receive immunosuppressive therapies (p=0.0002). MRI in MOG-antibody positive patients (4) less frequently demonstrated periependymal lesions (p=0.001), (5) more often were unspecific (p=0.004) and (6) resolved more frequently (p=0.016). 67% of all children presenting with NMO or limited forms tested positive for MOG- or AQP4-antibodies. MOG-antibody positivity was associated with distinct features. We therefore recommend to measure both antibodies in children with demyelinating syndromes.

Lechner C ，Baumann M ，Hennes EM ，Schanda K ，Marquard K ，Karenfort M ，Leiz S ，Pohl D ，Venkateswaran S ，Pritsch M ，Koch J ，Schimmel M ，Häusler M ，Klein A ，Blaschek A ，Thiels C ，Lücke T ，Gruber-Sedlmayr U ，Kornek B ，Hahn A ，Leypoldt F ，Sandrieser T ，Gallwitz H ，Stoffels J ，Korenke C ，Reindl M ，Rostásy K ... -  《-》

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Mader S ，Gredler V ，Schanda K ，Rostasy K ，Dujmovic I ，Pfaller K ，Lutterotti A ，Jarius S ，Di Pauli F ，Kuenz B ，Ehling R ，Hegen H ，Deisenhammer F ，Aboul-Enein F ，Storch MK ，Koson P ，Drulovic J ，Kristoferitsch W ，Berger T ，Reindl M ... -  《Journal of Neuroinflammation》

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S ，Ruprecht K ，Kleiter I ，Borisow N ，Asgari N ，Pitarokoili K ，Pache F ，Stich O ，Beume LA ，Hümmert MW ，Trebst C ，Ringelstein M ，Aktas O ，Winkelmann A ，Buttmann M ，Schwarz A ，Zimmermann H ，Brandt AU ，Franciotta D ，Capobianco M ，Kuchling J ，Haas J ，Korporal-Kuhnke M ，Lillevang ST ，Fechner K ，Schanda K ，Paul F ，Wildemann B ，Reindl M ，in cooperation with the Neuromyelitis Optica Study Group (NEMOS) ... -  《Journal of Neuroinflammation》

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Kitley J ，Waters P ，Woodhall M ，Leite MI ，Murchison A ，George J ，Küker W ，Chandratre S ，Vincent A ，Palace J ... -  《-》

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.

Rostásy K ，Mader S ，Hennes EM ，Schanda K ，Gredler V ，Guenther A ，Blaschek A ，Korenke C ，Pritsch M ，Pohl D ，Maier O ，Kuchukhidze G ，Brunner-Krainz M ，Berger T ，Reindl M ... -  《-》